NCT03719326 2024-05-24
A Study to Evaluate Safety/Tolerability of Immunotherapy Combinations in Participants With Triple-Negative Breast Cancer or Gynecologic Malignancies
Arcus Biosciences, Inc.
Phase 1 Completed
Clinical Trials
4 trialsNCT03961698 2023-08-14
MARIO-3
Infinity Pharmaceuticals, Inc.
Phase 2 Unknown
NCT03980041 2022-11-25
Study to Evaluate the Efficacy/Safety of IPI-549 in Combination With Nivolumab in Patients With Advanced Urothelial Carcinoma (MARIO-275)
Infinity Pharmaceuticals, Inc.
Phase 2 Completed
NCT02637531 2022-04-04
A Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IPI-549
Infinity Pharmaceuticals, Inc.
Phase 1 Unknown